Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Web Exclusives
Researchers Released Data from a Clinical Trial Investigating Fluorine 18 Fluciclovine PET/CT Use to Identify Targets for Site-Directed Therapy
Prostate Cancer Diagnostics
Web Exclusives
— September 29, 2021
Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.
Read Article
Phase 3 INDICATE Trial Evaluating the Use of Apalutamide in Patients with Biochemical Recurrence of Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
— September 29, 2021
Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.
Read Article
Androgen Deprivation Therapy at Time of Fluorine 18 Fluciclovine PET/CT More Likely to Return a Positive Scan
Prostate Cancer Diagnostics
Web Exclusives
— September 29, 2021
Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.
Read Article
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
Cholangiocarcinoma
,
Personalized Medicine
Web Exclusives
— August 10, 2021
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
Read Article
Sponsored
Innovative Technology Supports Value-Based Care Success
By
Amy Valley, PharmD
Value-Based Care
Web Exclusives
— June 29, 2021
The demands of value-based care have continued to evolve since oncologists began transitioning from fee-for-service to fee-for-value reimbursement more than five years ago. For community-based oncology practices, more change is coming with the introduction of the Oncology Care First Model, the successor of the current Oncology Care Model (OCM). Following a one-year delay caused by the pandemic, the Centers for Medicare & Medicaid Services is expected to launch the Oncology Care First Model in 2022 and will likely include a larger number of practices than the OCM.
Read Article
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
In the Literature
,
Leukemia
Web Exclusives
— April 13, 2021
Induction chemotherapy leads to remission in many patients with acute myeloid leukemia (AML) aged ≥60 years; however, the disease relapses in the majority of the patients, and the overall survival (OS) is poor. For patients who are not candidates for hematopoietic stem-cell transplant, effective maintenance treatments for AML are needed that can reduce the risk for relapse and improve OS, without causing unacceptable adverse events or compromising quality of life.
Read Article
Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer
In the Literature
Web Exclusives
— April 13, 2021
Patients with triple-negative breast cancer (TNBC) have a high relapse rate and poor outcome after standard treatment. Capecitabine (Xeloda), a chemotherapy that has been used widely in the treatment of metastatic breast cancer, is a potential maintenance treatment option for the prevention of TNBC recurrence based on results of a recent study.
Read Article
Enfortumab Vedotin Demonstrates Superior Efficacy versus Chemotherapy in Bladder Cancer
Bladder Cancer
,
In the Literature
Web Exclusives
— April 13, 2021
Patients with advanced urothelial carcinoma and disease progression after treatment with platinum-based chemotherapy and PD-1 or PD-L1 inhibitors have limited treatment options. Enfortumab vedotin (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, demonstrated an objective response rate (ORR) in more than 40% of patients with advanced urothelial carcinoma who had progression after previous treatment.
Read Article
Webinar Panelist Discusses COVID-19 and Hematology Oncology Pharmacy
COVID-19
Web Exclusives
— August 11, 2020
David DeRemer, PharmD, BCOP, FCCP, FHOPA, Clinical Associate Professor, University of Florida College of Pharmacy, shares insights about cancer drugs and COVID-19 in this interview that followed a segment of the Association for Value-Based Cancer Care (AVBCC) webinar series
COVID-19 Recovery, the Road Ahead
, in which he recently took part.
Read Article
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
FDA Approvals, News & Updates
Web Exclusives
— June 22, 2020
On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer.
Read Article
Page 2 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma